For millions of adults still grappling with crushing fatigue months after a COVID-19 infection, the absence of proven therapies has been a source of profound frustration. A placebo-controlled trial now offers a credible pharmacological candidate — and the mechanism behind it may reshape how clinicians think about long COVID's biological underpinnings.
The adaptive randomized trial enrolled 399 Brazilian adults with fatigue persisting at least 90 days following confirmed SARS-CoV-2 infection. Participants received fluvoxamine (100 mg twice daily), metformin (750 mg twice daily), or placebo for 60 days. Fluvoxamine — an SSRI best known for OCD treatment but also a potent sigma-1 receptor agonist with anti-inflammatory properties — produced a statistically meaningful reduction in Fatigue Severity Scale scores versus placebo at day 60 (mean difference −0.43; 95% credible interval −0.80 to −0.07), with the effect strengthening at the 30-day post-treatment follow-up (mean difference −0.58). Quality-of-life measures also improved with high posterior probability. Metformin, despite mechanistic rationale involving mTOR suppression and mitochondrial support, showed no significant fatigue benefit. Notably, fluvoxamine's adverse event rate (20%) was lower than both metformin (28.8%) and placebo (29.7%), suggesting reasonable tolerability.
The fluvoxamine finding is scientifically plausible beyond its serotonin reuptake activity. As a sigma-1 receptor agonist, it modulates neuroinflammation and endoplasmic reticulum stress — pathways increasingly implicated in post-viral syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome. This mechanistic overlap is important context: long COVID fatigue may be neuroinflammatory rather than purely psychological, a distinction that affects treatment targeting. Metformin's null result is somewhat surprising given earlier observational data suggesting benefit in long COVID broadly, though those studies weren't fatigue-specific. Key limitations include a 90-day total follow-up insufficient to assess durability, a single-country sample that may limit generalizability, and the trial's exclusive focus on fatigue rather than the full long COVID symptom constellation. This is incremental but meaningful evidence — not practice-changing alone, but compelling enough to justify larger, longer replication trials across diverse populations.